TIONAL WORKSHOP O AL TRACT ATHOLOGYhpvrome.com/program.pdf4 TIONAL WORKSHOP O AL TRACT ATHOLOGY FACULTY PRO M. Barbero - Italy M. Benevolo - Italy A. Biamonti- Italy F. Boselli - Italy

1

XIII INTERNATIONAL WORKSHOP ON LOWER GENITAL TRACT PATHOLOGY

Course Directors

P. Davies A. Frega C. Gentili

International Scientific Committee

A. Ciavattini - Italy R. De Vincenzo - Italy J. Dillner - SwedenD. French - Italy A. Lukic - Italy B. Moscicki - U.S.K.U. Petry - Germany W. Prendiville - France

Organising Secreatariat

Adria CongrexVia Sassonia, 30 - 47922 RiminiTel. 0541 305811 [email protected]

2


Thursday, April 12 2018

TIME ROOM A ROOM B

08.30 – 08.50 OPENING LECTURE

08.50 – 10.20 HPV INFECTION AND CARCINOGENESIS

10.20 – 11.00 EPIDEMIOLOGY OF CERVICAL CANCER AND

HPV INFECTION

11.00 – 11.30 BREAK

11.30 – 13.00 CERVICAL SCREENING

13.00 – 13.30 LECTURE SPONSORED BY FARMITALIA

13.30 – 14.00 LECTURE SPONSORED BY BIOSTILOGIT

14.00 -14.30 LUNCH

14.30 - 15.40 CERVICAL SCREENING: THE NEW CHALLENGES

UPDATES IN MOLECULAR BIOLOGY

15.40 – 16.50 HPV POSITIVE, WHAT NEXT?

UPDATES IN CYTOPATHOLOGY

16.50 – 17.10 BREAK

17.10 – 18.00 COLPOSCOPY IN THE ERA OF HPV VACCINATION AND

HPV SCREENING ASK THE EXPERT

18.00 – 18.55 NONCOMPLIANCE WITH REFERRAL TO

COLPOSCOPY

PROGRAM AT A GLANCE

3


Friday, April 13 2018

TIME ROOM A ROOM B

08.30 – 10.40 VACCINATION FREE COMMUNICATIONS

10.40 – 11.10 BREAK

11.10 – 13.00 ENSURING THE SAFETY AND EFFECTIVENESS OF

COLPOSCOPY

FREE COMMUNICATIONS

13.00 – 13.30 LECTURE SPONSORED BY SHIONOGI

13.30 -14.30 LUNCH

14.30 – 15.40 PUBLIC EDUCATION AND COVERAGE RATES

PAP SMEAR: NEVER SAY NEVER AGAIN

15.20 – 17.20 THE CERVICAL CYTOPATHOLOGY IN THE

HPV TESTING ERATHE CERVICAL

CYTOPATHOLOGY IN THE HPV TESTING ERA

16.30 – 17.40 MISCELLANY

17.20 – 18.20 AWARDS AND CONCLUSIONS

4


FACULTY

PRO

M. Barbero - ItalyM. Benevolo - ItalyA. Biamonti- ItalyF. Boselli - ItalyE. Carico - Italy

D. Caserta - ItalyA. Castanon - U.K.

M. Cruickshank - U.K.P. Davies - Belgium

R. De Vincenzo - ItalyF. De Seta - Italy

J. Dillner - Sweden L. Dillner - Sweden

J. Doorbar - U.K.E. Giarnieri - Italy

M.R. Giovagnoli - ItalyM. Goodmam - U.S.

W. Huh - U.S.L. Mariani - Italy

B. Moscicki - U.S.P. Martin Hirsch - U.K.

G. Negri - ItalyM. O’Connor - Ireland

M. Peroni - Italy K.U. Petry - Germany

W. Prendiville - France W. Ricciardi - ItalyG. Scambia - ItalyR. Senatori- Italy

F. Sopracordevole - ItalyU. Tabuica - Moldova

F. Torcia - ItalyA. Venuti - ItalyJ. Waller - U.K.

C. Zanardi - Italy

5


PRO

PROGRAM

Thursday 12 / Friday 13 April 2018

6


Registration

Welcome P. Davies.-A. Frega - C. Gentili

ROOM A (Plenary session)

8.00

8.20

Opening Lecture Chairman: G. Scambia HPV infection and carcinogenesis: a public health perspective.W. Ricciardi

HPV infection and CarcinogenesisChairpersons: P. Davies - A. Venuti

Human papillomavirus infection and the induction of neoplasia.J. Doorbar The natural history of HPV infection in screening age women: do we have enough data to really understand what is happening in this age group?B. Moscicki Persistent vs repeated infections: can we tell the difference and does it make a difference to cervical carcinogenesis? J. Doorbar New hot topics. HPV in non HIV immunocompromised men and women: screening and manegement.B. Moscicki Discussion

Epidemiology of Cervical Cancer and HPV InfectionChairpersons: A. Castanon – A.Lukic Cervical cancer trends around the world: are we making a difference?P. DaviesHPV vaccination and its impact on HPV infection rates around the world.J. Dillner

8.30

8.50-10.20

8.50-9.10

9.10-9.30

9.30-9.50

9.50-10.10

10.10-10.20

10.20-11.00

10.20-10.40

10.40-11.00

Thursday 12 April 2018

Morning

7


Cervical ScreeningChairpersons: J. Dillner - C. Gentili

The current status of cervical screening programmes around the world: are we making progress where it is needed most or just improving the best?M. Goodman HPV testing for primary screening: who is doing what?A. Castanon The latest data from the HPV primary screening programmes: the benefits and the challenges that remain to be solved.M. GoodmanCervical screening: is there still a role for the Pap test?P. DaviesDiscussion

LECTURE SPONSORED BY FARMITALIA - NON ECMVulvovaginitis & HPV infection: diagnostic and therapeutic issues M. Sansone LECTURE SPONSORED BY BIOSTILOGIT - NON ECMEllacid acid/acetogenins annonaceus supplement: effects on cervical HPV related preneoplastic lesionsM. Le Donne

11.30-13.00

11.30-11.50

10.50-12.10

12.10-12.30

12.30-12.50

12.50-13.00

13.00 - 13.30

13.30 -14.00

Cervical Screening: the New ChallengesChairpersons: A. Biamonti - U. Petry

Estimating the impact of HPV primary screening and HPV vaccination on cervical cancer rates.A. Castanon The evolution of HPV testing in the U.SW. HuhHPV screening recall and follow-up recommendations: do doctors stick to the rules? M. GoodmanDiscussion

HPV Positive: what Next?Chairpersons: M. Cruickshan - M. Peroni

HPV positive: what are the triage options and their associated risksK.U. Petry

14.30-15.40

14.30-14.50

14.50-15.10

15.10-15.30

15.30-15.40

15.40-16.50

15.40-16.00

Afternoon

ROOM A

8


ROOM B

Updates in Molecular BiologyChairpersons: D. French - A. Venuti

Latent papillomavirus infections: the role of the HPV test. J. DoorbarGetting around in the molecular testing jungle: what clinicians and pathologists should know to properly interpret the results. L. Dillner

14.30-16.00

14.30-14.50

14.50-15.10

How does HPV status affect the treatment of low-grade cervical disease?P. Martin HirschPersistent HPV Infection without colposcopically visible cervical disease: how common and what is it the appropriate follow-up? K.U. PetryDiscussion

Colposcopy in the Era of HPV Vaccination and HPV ScreeningChairpersons: W. Huh - F. Sopracordevole

The implications of HPV vaccination for the practice of colposcopy.M. Cruickshank HPV primary screening: will this affect the accuracy of colposcopy?P. Martin Hirsch Should colposcopists be re-trained to deal with the realities of the HPV eraK.U. Petry Discussion

Noncompliance with Referral to ColposcopyChairpersons: P. Martin Hirsch - C. Zanardi

Noncompliance with colposcopy referral: the extent of the problem in different countries. U. TabuicaWhy do women decide not to go to colposcopy? M. Cruickshank,Understanding and reducing the adverse psychological impact of colposcopyJ. WallerDiscussion

16.00-16.20

16.20-16.40

16.40-16.50

17.05-18.00

17.05-17.20

17.20-17.35

17.35-17.50

17.50-18.00

18.00-18.55

18.00-18.15

18.15-18.30

18.30-18-45

18.45-18.55

9


Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a. J. DoorbarThe role of cytology and HPV genotyping in screening for anal cancer.B. MoscickiDiscussion

Updates in Cytopathology Chairpersons: M. Benevolo – E. Giarnieri

Is the new Bethesda system tailored for HPV screening and molecular diagnosis?M.R. GiovagnoliCytology triage: what molecular testing cannot provide.G. Negri Discussion

Ask the ExpertsCoordinators: P. Davies- A. Frega- C. Gentili

Open forum: what would you like to ask a panel of experts? R. De Vincenzo, J. Dillner, G. Negri, M. O’Connor, W. Prendiville

15.10-15.30

15.30-15.50

15.50-16.00

16.00-16.50

16.00-16.20

16.20-16.40

16.40-16.50

17.10-18.45

10


Friday 13 April 2018

Morning


VaccinationChairpersons: M. Cruickshank - A. Lukic

HPV vaccination around the world today: the programs and the coverage rates.J. DillnerHPV vaccination: long-term efficacy and protection. What are the data?R. De Vincenzo Screening in vaccinated and unvaccinated women: are two algorithms necessary and if so how do we implement them?M. O’Connor,HPV vaccination of boys: who is doing what? J. DillnerImproving HPV vaccination coverage: what works and what doesn’t. J. WallerThe nonavalent HPV vaccine: what changes?L. MarianiDiscussion

Ensuring the Safety and Effectiveness of ColposcopyChairpersons: A.Ciavattini - M. O’Connor

Adverse sequelae after the treatment of CIN: an international comparison P. Martin Hirsch Treatment of cervical pre-cancer: current best practicW. Prendiville Colposcopy training: the similarities and differences across Europe.M. CruickshankTraining colleagues in middle income countries W. Prendiville Quality assurance of colposcopy: the European perspective K.U. PetryQuality assurance of colposcopy: the American perspective. W. HuhDiscussion

8.30-10.40

8.30-8.50

8.50-9.10

9.10-9.30

9.30-9.50

9.50-10.10

10.10-10.30

10.30-10.40

11.10-13.00

11.10-11.30

11.30-11.50

11.50-12.05

12.05-12.20

12.20-12-35

12.35-12.50

12.50-13.00

11


ROOM B

Free CommunicationChairpersons: A. Biamonti- R. Barbero – E.Carico

HPV INFECTION AND CANCEROGENESISCase-control study on the efficacy ofcarboxymethylbetaglucan-lactoferrin association in women with high-risk Human Papillomavirus (HPV) uterine cervical infectionA.A. Criscuolo, E. Guri, M. Ciotti, F. Sesti, E. Piccione

CERVICAL SCREENINGReducing unnecessary colposcopy by risk discrimination. HPV genotyping with NILM or low-grade cytology in screening paradigms: systematic review J. AndrewsRisk of invasive lesions in cytologically atypical glandular cells (AGC) on conventional Pap Test: follow up studyE. IsidoroPrimary cervical cancer screening with a 5-type HPV e6/e7 mRNA test: results of 10 years follow-upS.W. Sørbye , A.Rad , F.E. SkjeldestadHPV test in triage of ASC-US/LSIL - the risk of CIN3+ in 5-type HPV E6/E7 mRNA negative womenS.W. Sørbye, M.M. Slettebak, F.E. Skjeldestad Cytology and 3-type HPV e6/e7 mRNA co-testing in women 25-33 yearsS.W . Sørbye, F.E. . Skjeldestad FEDetection of CIN2+ in women with normal cytology - the added value of a 3-type HPV E6/E7 mRNA testS.W. Sørbye, B. Westre, A. Giske, H. Guttormsen, F.E. Skjeldestad Discussion

COLPOSCOPYSmartscopy: the speculoscopy applied to the smartphone can be an efficient alternative to the traditional one?C. Bondi, A. Palmeri, M. Maramai, F. CasabonaEndocervicoscopy: a new imaging technique and its accuracy in studing cervical intrapithelial lesionN. De Rosa, G. Lavitola, M.Palma, R.Gallo, M.C Pagliuca, C. Di Filippo, G. Bifulco

8.30-11.00

8.30 – 8.37

8.37 – 8.44

8.44-8.58

8.51-8.58

8.58-9.05

9.05-9.12

9.12-9.19

9.19-9.29

9.29-9.36

9.36-9.43

LECTURE SPONSORED BY SHIONOGY - NON ECMPapilocare vaginal gel innovative therapy for the treatment of LSIL P. Inghirami

13.00-13.30

12


How to use a low cost CCD camera for hysteroscopy and colposcopy: our “all-in-one” deviceM. Maramai, C. Bondi, A. Palmeri, F. Casabona LSIL: colposcopic pictures and indication to direct biopsy. A study of the SICPCVM.Serri, F. Sopracordevole, P.Garutti, M. Fallani, B. Gardella, P.Scirpa, M.T. Schettino, A. Del Fabro, A. Pieralli, F. Ravennati, S.Montori, R.Agrusti, M.Papiccio, A.C.Boschi, M.R. Primieri, F. Cigolot, A. CiavattiniEvidence for clinical utility of extended HPV genotyping in persistence tracking and follow-up after abnormal results and colposcopyJ. AndrewsDiscussion

MISCELLANYLymphoma of the lower female genital tractR. Sparic, A. Dobrosavljevic, J. Stulic, L. NejkovicTubulosquamos polyp in vagina together with VAIN II/IIIR. Sparić, J.Stulic, A. Dobrosavljevic, L. NejkovicDiscussion

Free CommunicationsChairpersons: D. French - E. Giarnieri - R. Senatori

EPIDEMIOLOGY OF CERVICAL CANCER AND HPV INFECTIONThe risk of cervical atypia in oral contraceptive usersI. Adhikari, T.Eriksson, T. Luostarinen, M.Lehtinen, D.ApterCountries of Eastern Europe and Central Asia: the situation of HPV infection in HIV-positive womenA.A. Popova, O.Y. Shipulina, M.O. DeulinaPrevalence of cervical HPV lesions in patients with bowel inflammatory diseases in immunosuppressive treatment and cervical screening: multidisciplinary management experience in a referral centerC.Ricci, F.Scaldaferri, F. Colombo, A. Gasbarrini, G. Scambia, R. De VincenzoRole of vaginal TIAB in cervical reepithelialisation and high-risk HPV clearance in patients with low-grade cervical lesionsC.Ricci, M.T.Evangelista, G. Scambia, R. De Vincenzo HPV-HR prevalence and type distribution in women with NILM or HSIL Pap smear in Russia.O.Y. Shipulina, M.Y. Dmitryukova, G.V.LeshkinaDiscussion

9.43-9.50

9.50-9.57

9.57-10.04

10.04-10.14

10.14-10.21

10.21-10.28

10.28-1040

11.10 – 13.30

11.10-11.17

11.17-11.24

11.24-11.31

11.31-11.38

11.38-11.45

11.45-11.55

13


MOLECULAR BIOLOGY AND CYTOPATHOLOGYThe risk of developing a CIN2+ lesion in women with HPV16 and 18, versus women with other HPV types: follow-up studyE. Isidoro, U. Wiesenfeld, M. Di Napoli, A. Romano, J. Dobric, C. Biagi, F. Variola, S.Tomasi, D.Santon, S.Dudine, F. Giudici, L. Di Bonito, F. Zanconati Mesenchymal stem cells from cervix: what is about age and inflammation?G. Delli Carpini, M. Orciani, M. Caffarini, R. Lazzarini, S. Guizzardi, D. Tsiroglou, R. Di Primo, A. CiavattiniMolecular study of HPV-related oropharyngeal carcinomaG. Ferrario, P. Morbini, P. Alberizzi, M. BenazzoHR-HPV negative cases of cytological HSIL and additional testing results for low and unknown risk types.G.V. Leshkina, O.Y. Shipulina, T.N. RomanyukDNA HPV testing and diagnostic cytopathology for oral cancer screening Navone R., Amodeo E., Lapucci C., Crò F., Pentenero M., Gandolfo S.Expression of E6/E7 HPV-DNA, HPV-mRNA and colposcopic features in management of CIN2/3 during pregnancyC. Leone, D. French, M. Pavone, A. Frega, D. CasertaDiscussion

TREATMENT AND FOLLOW-UP Evidence for clinical utility of extended HPV genotyping in Test of Cure after treatment of CIN2+J. AndrewsRadiofrequency and poration for the treatment of HPV genital warts: a case reportC. CatalisanoRole of “close” negative endocervical margin in treatment failure after cervical excision for cervical intraepithelial neoplasia: a retrospective studyG. Delli Carpini, A. Del Fabro, L. Alessandrini, M. Buttignol, V. Canzonieri, A. Cagnacci, F. Sopracordevole, A. CiavattiniLLETZ in woman of reproductive age diagnosed with squamous intraepithelial lesions: the problem of specimen artifactsR.Sparic, S.Kadija, R. Stefanovic, L.Jovanovic, T. Janjic, J.Bila, M. BerisavacDiscussion

11.55-12.02

12.02-12.09

12.09-12.16

12.16-12-23

12.23-12.30

12.30-12.37

12.37-12.47

12.47-12.54

12.54-13.01

13.01-13.08

13.08-13.15

13.15-13.25

14


ROOM A

Afternoon

Public Education and Coverage Rates Chairpersons: F.Boselli - W.Prendiville

Social and psychological impact of HPV testing in cervical screening. J. WallerReaching under- or never-screened women: is self-sampling the answer? L. Dillner,The impact of HPV vaccination on cervical cancer screening coverage: are the predictions proving to be true? M. CruickshankHPV vaccination for adolescents, Pap screening for under-30’s, HPV screening for over 30’s: how can we effectively communicate all this to ensure high programme participation? M. O’ConnorDiscussion

HPV and Vaginal InfectionChairpersons: A. Biamonti - U. Tabuica

The role of vaginal microbiome in HPV infection and disease. B. Moscicki Chlamydia trachomatis infection: epidemiology, treatment and its role in HPV disease F. De Seta,The effect of intrauterine devices on acquisition and clearance of human papillomavirusB. Moscicki Discussion

MiscellanyChairpersons: R. Senatori- F. De Seta

HPV and fertility. D. CasertaPotential innovations in cervical precancer management W. Prendiville,The role of oral contraception and hormone replacement therapy in HPV infection and disease. F. Torcia The ultrasound in the evaluation of preneoplastic and neoplastic lesions of the uterine cervix U. TabuicaDiscussion

14.30-15.40

14.30-14.45

14.45-15.00

15.00-15.15

15.15-15.30

15.30-15.40

15.40-16.30

15.40-15.55

15.55-16.05

16.05-16.20

16.20-16.30

16.30-17.40

16.30-16.45

16.45-17.00

17.00-17.15

17.15-17.30

17.30-17.40

15


The Cervical Cytopathology in the HPV Testing EraCoordinators: M.R. Giovagnoli - G. NegriAn interactive seminar slide of cervical cytopathology.

15.20-17.40


Presentation of the Best 3 Free Communications and Award for the BestChairpersons: P. Davies - A. Frega - C. Gentili

General Discussion

ECM Test

Prize Giving for the Three Best Speakers and Conclusions

17.40-18.00

18.00-18.10

18.10-18.20

18.20-18.30

ROOM B

Pap Smear: Never Say Never AgainChairpersons: M. Benevolo – E. Carico

Don’t forget me: cytology of HPV negative lesions. G. NegriWhat clinicians need from cytology. W. HuhDiscusison

14.30-15.20

14.30-14.50

14.50-15.10

15.10-15.20

17


GENERAL INFORMATION

18


1. Cic Editore2. Becton Dickinsons Italia 3. Farmitalia 4. Digi Medica Snc5. Fujirebio Europe6. IDI Pharma7. Bio Stilogit Pharmaceuticals 8. S&R Farmaceutici 9. smart10. Morgan 11. Synlab Italia

12. Centrel 13. Difass International 14. Arrow Diagnostics 15. EuTylia16. Sakura Italia 17. Roche Diagnostics18. Depofarma 19. Hologic Italia 20. Farma-Derma21. Verduci Editore

19


EXHIBITION AREANH Hotel Villa Carpegna | ROMA

20


GENERAL INFORMATION

CONGRESS VENUENH Hotel Villa CarpegnaVia Pio IV, 6 | 00165 ROMA (RM) | Tel +39 06 393731www.nh-hotels.it/hotel/nh-roma-villa-carpegna

LANGUAGE English will be the ufficial language of the Workshop. Simultaneous translation into Italian will be provided.

ITALIAN ECM ACCREDITATION The meeting will be accredited for the ECM credits for Italian doctors.To obtain credits it is necessary to attend the meeting. No promotional activities will be permitted in the same room before, during, or after an ECM activity.The specialities and disciplines able to apply for Italian ECM credits are:

Medico Chirurgo: Anatomia Patologica; Igiene, Epidemiologia e Sanità Pubblica; Ginecologia e Ostetricia; Oncologia; Patologia Clini-ca (laboratorio di analisi chimico-cliniche e microbiologia)Biologo: Anatomia Patologica; Igiene, Epidemiologia e Sanità Pubblica; Patologia Clinica (laboratorio di analisi chimico-cliniche e microbiologia)Tecnico di laboratorio biomedicoInfermiere ed ostetrica

SPONSOR

Black

Documents

TIONAL WORKSHOP O AL TRACT ATHOLOGYhpvrome.com/program.pdf4 TIONAL WORKSHOP O AL TRACT ATHOLOGY FACULTY PRO M. Barbero - Italy M. Benevolo - Italy A. Biamonti- Italy F. Boselli - Italy